You are here

Article Text

Article menu
Download PDFPDF
Letter
Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis
  1. H Marotte1,
  2. G Paintaud2,
  3. H Watier2,
  4. P Miossec1
  1. 1
    Departments of Immunology and Rheumatology, Lyon, France
  2. 2
    François Rabelais University, Tours, France
  1. Professor P Miossec, Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Hérriot, 69437 Lyon Cedex 03, France; miossec{at}univ-lyon1.fr

https://doi.org/10.1136/ard.2007.081166

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rituximab is effective in B-cell lymphomas but also in inflammatory diseases such as rheumatoid arthritis (RA).1 Several cases of late-onset neutropenia (LON) have been described in lymphomas.2–4 Reversible rituximab-related LON tends to occur 2–6 months after rituximab administration. The post-marketing rate of LON appears very low (<0.02% in a total of 300 000 patients).2 Its mechanism is unknown, although several hypotheses have been suggested.

    We report one case of rituximab-related LON for the first time outside the lymphoma field and explore some of the proposed …

    View Full Text

    Footnotes

    • Competing interests: None declared.